The UNMC College of Medicine received grant and funding awards representing $3.5 million in new funding in July.
Jawed Siddiqui, PhD, biochemistry and molecular biology, received a grant of $926,000 from the U.S. Army/USAMRAA/CDMRP for a study targeting novel GDF15/GFRAL/RET axis in prostate cancer bone metastasis.
Kaustubh Datta, PhD, biochemistry and experimental biology, received a grant of $766,117 from the U.S. Army/USAMRAA/CDMRP for a study on Neuropilin-2 inhibitor as a potent therapy for prostate cancer bone metastasis.
Santhi Gorantla, PhD, pharmacology and experimental neuroscience, received a grant of $688,500 from DHHS/NIH/NINDS for HIV-1 Detection and Elimination From CNS Mononuclear Phagocytes. Dr. Gorantla also received a grant of $537,030 from DHHS/NIH/NIDA to study the impact of drugs of abuse on HIV brain reservoirs and HAND in humanized microglia mice.
Yutong Liu, PhD, radiology, received a grant of $191,302 from DHHS/NIH/NIMH for CNS HIV theranostics based on intrinsic CEST contrasts of antiretroviral drugs.
Siwei Zhao, PhD, surgery-transplant, received a grant of $178,307 from DHHS/NIH/NIAMS for a hydrogel ionic circuit-based electrical stimulation system for preservation of denervated muscles.
Todd Wyatt, PhD, pathology/microbiology, received a grant of $13,817 from the VA Medical Center-Omaha as an IPA for St. Patrick Reid, PhD.
Industry-sponsored grants and contracts:
The following industry-sponsored contracts and foundation grants were received. Information on clinical trials enrolling patients at UNMC can be found here.
Chi Zhang, MD, PhD, radiation oncology, received funding for a phase I/II study to test the immunostimulatory effects of consolidative hypofractionated radiation therapy (hfRT) for boosting the residual primary lung cancer in combination with anti-PD-L1 immunotherapy after definitive chemoradiation therapy.
Julie Vose, MD, Internal medicine-oncology/hematology, received funding for a phase 1B/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of Tazemetostat or placebo in combination with Lenalidomide plus Rituximab in subjects with relapsed/refractory follicular lymphoma.
Jamie Wilson, MD, neurosurgery, received funding for a phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MT-3921 in subjects with acute traumatic cervical spinal cord injury.
Kelsey Klute, MD, internal medicine-oncology/hematology, received funding for a SOW#2 analysis cohort or main protocol.